Adverse events with Gilead’s GS 9190 may increase HCV polymerase inhibitor scrutiny
This article was originally published in Scrip
Executive Summary
Following the reports of two serious adverse events in two separate Phase IIb studies of GS 9190 in hepatitis C-infected patients, Gilead Sciences is amending the trial designs and discontinuing dosing of the drug candidate, following consultation with the US FDA.